ClinicalTrials.gg
CompletedNCT04511624Updated Sep 19, 2022

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

A Phase 1 interventional study of IBI112 dose1 and IBI112 dose2 in Healthy Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-19.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a the first in human study to evaluate the safety, tolerability, PK and PD of single subcutaneous or intravenous dose of IBI112 in healthy subjects

Read the detailed description

In this first in human, phase 1, randomized, double-blind, placebo-controlled study, a single subcutaneous or intravenous dose of IBI112 will be administered to 46 healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female 18 to 45 years of age at the time of consent
  2. of 19-26Kg/m2 and weight of 50-100kg
  3. Must provide written , and in the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a medical history of liver, kidney, cardiovascular, nervous / mental, gastrointestinal, respiratory, urinary, endocrine
  2. Subjects who have a history of relapse or chronic infection, or a history of acute infection within 2 weeks;
  3. Subjects who have previously used anti-IL-12 / 23 or anti-il-23 drugs;
  4. Subjects who have abnormalities determined by vital signs, physical examination, and laboratory measurements;
  5. Subjects who are not suitable for this trial due to other reasons In the investigator' opinion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Cohort 1

    IBI112 SC dose1

    Drug: IBI112 dose1

  • Experimental
    Cohort 2

    IBI112 SC dose2

    Drug: IBI112 dose2

  • Experimental
    Cohort 3

    IBI112 SC dose3

    Drug: IBI112 dose3

  • Experimental
    Cohort 4

    IBI112 IV dose4

    Drug: IBI112 dose4

  • Experimental
    Cohort 5

    IBI112 IV dose3

    Drug: IBI112 dose5

  • Experimental
    Cohort 6

    IBI112 SC dose5

    Drug: IBI112 dose6

  • Experimental
    Cohort 7

    IBI112 IV dose5

    Drug: IBI112 dose7

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of IBI112

    Time frame: Day1 to Day 113 post dose

Secondary outcomes

  1. Maximum Concentration (Cmax) - Pharmacokinetic Assessment

    IV dose \& SC dose

    Time frame: Day 113

  2. Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment

    SC dose

    Time frame: Day 113

  3. Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment

    IV dose \& SC dose

    Time frame: Day 113

  4. Half-Life (t1/2) - Pharmacokinetic Assessment

    IV dose \& SC dose

    Time frame: Day 113

  5. Volume of Distribution (Vd) - Pharmacokinetic Assessment

    IV dose \& SC dose

    Time frame: Day 113

07

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jul 2022, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2020
First posted
Aug 13, 2020
StartActual
Aug 27, 2020
Primary completionActual
Jul 22, 2022
CompletionActual
Jul 22, 2022
Last update
Sep 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04511624
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Aug 27, 2020
Primary completion
Jul 22, 2022
Completion
Jul 22, 2022
Last update
Sep 19, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI112

Start the discussion